Inclusion Criteria:
- Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker
analysis
- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and
at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion
biopsies are not acceptable.
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Radiographically documented progressive disease on or after the most recent therapy
- Received standard-of-care therapies, (except for Part 1C, where participants with
prior docetaxel use for the advanced/metastatic setting will be excluded), including
an available programmed death (ligand)-1 inhibitor known to be effective in the tumor
type for which they are being evaluated
- Advanced or metastatic disease and have received, be refractory to, not be a candidate
for, or be intolerant of existing therapies known to provide clinical benefit for the
condition of the participant
Exclusion Criteria:
- Women who are pregnant or breastfeeding
- Primary central nervous system (CNS) malignancy
- Untreated CNS metastases
- Leptomeningeal metastases
- Concurrent malignancy requiring treatment or history of prior malignancy active within
2 years prior to the first dose of study treatment
- Active, known, or suspected autoimmune disease
- Condition requiring systemic treatment with either corticosteroids within 14 days or
other immunosuppressive medications within 30 days of the first dose of study
treatment
- Prior organ or tissue allograft
- Uncontrolled or significant cardiovascular disease
- Major surgery within 4 weeks of study drug administration
- History of or with active interstitial lung disease or pulmonary fibrosis
Other protocol-defined inclusion/exclusion criteria apply
Recruiting
